DGIdb - NINTEDANIB Drug Record

NINTEDANIB chembl:CHEMBL502835 ApprovedAntineoplastic

Alternate Names:

VARGATEF
BIBF1120
NINTEDANIB
OFEV
BIBF-1120
INTEDANIB
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
OFEV®
VARGATEF®
BIBF 1120
drugbank:09079
chembl:CHEMBL502835
chemidplus:656247-17-5
rxcui:1592737
pubchem.compound:9809715

Drug Info:

Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Drug Categories	antifibrotic agents
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates (strength unknown)
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	kinase inhibitor
Drug Categories	oct1 inhibitors
Drug Categories	oct1 substrates
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	tyrosine kinase inhibitors
Drug Categories	ugt1a1 substrates

(7 More Sources)

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem

NINTEDANIB FLT1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB FGFR3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB FLT4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB FGFR1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB FGFR2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Notes

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Publications:

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

NINTEDANIB PDGFRA

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

NINTEDANIB KDR

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name BIBF-1120,Vargatef

Notes

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB FGFR4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:

NINTEDANIB LYN

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB SRC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB FLT3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB LCK

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

NINTEDANIB FRK

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:
NINTEDANIB FGR

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:
NINTEDANIB HCK

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:
NINTEDANIB YES1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:
NINTEDANIB BLK

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:
NINTEDANIB FYN

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:
NINTEDANIB RET

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Pan-TK inhibitor

Alteration RET__.

Publications:
NINTEDANIB AKT1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
NINTEDANIB CFLAR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB09079

Version: 5.1.7

Alternate Names:

NINTEDANIB DrugBank Drug Name

656247-17-5 CAS Number

Ofev Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories antifibrotic agents

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

MyCancerGenome: NINTEDANIB
- Version: 20-Jun-2017
Alternate Names:

BIBF1120 Development Name

NINTEDANIB Generic Name

VARGATEF Trade Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: NINTEDANIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

DTC: NINTEDANIB

Version: 02-September-2020

Alternate Names:

CHEMBL502835 ChEMBL Drug ID

Drug Info:

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem

JAX-CKB: Nintedanib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
TALC: NINTEDANIB
- Version: 12-May-2016
Alternate Names:

NINTEDANIB Primary Drug Name

VARGATEF Drug Trade Name

BIBF 1120 Drug Synonym

Drug Info:

Publications:
TTD: Intedanib
- Version: 2020.06.01
Alternate Names:

D09HNV TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178102559
- Version: 29-September-2020
Alternate Names:

NINTEDANIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL502835
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
CGI: Nintedanib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: NINTEDANIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Notes
Trial Name	BIBF-1120,Vargatef
Novel drug target	Established target

Response Type	resistant
Indication/Tumor Type	urinary bladder cancer
Evidence Type	Actionable

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

NINTEDANIB	DrugBank Drug Name
656247-17-5	CAS Number
Ofev	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	antifibrotic agents

BIBF1120	Development Name
NINTEDANIB	Generic Name
VARGATEF	Trade Name

NINTEDANIB	Primary Drug Name
VARGATEF	Drug Trade Name
BIBF 1120	Drug Synonym

NINTEDANIB Drug Record

NINTEDANIB chembl:CHEMBL502835 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

Publications: Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res. Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Response Type resistant Indication/Tumor Type urinary bladder cancer Evidence Type Actionable

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

Publications: Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res. Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name BIBF-1120,Vargatef Novel drug target Established target Notes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

Publications: Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

Publications: Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name BIBF-1120,Vargatef Notes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications: Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res. Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications: Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res. Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res. Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications: Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res. Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Drug family Pan-TK inhibitor Alteration RET__.

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

DrugBank: DB09079

Alternate Names: NINTEDANIB DrugBank Drug Name 656247-17-5 CAS Number Ofev Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Categories antifibrotic agents

Publications: Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res. Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

MyCancerGenome: NINTEDANIB

Alternate Names: BIBF1120 Development Name NINTEDANIB Generic Name VARGATEF Trade Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: NINTEDANIB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

DTC: NINTEDANIB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Publications:

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name BIBF-1120,Vargatef

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Pan-TK inhibitor

Alteration RET__.

Interaction Types & Directionality:

n/a

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Interaction Types & Directionality:

n/a

Alternate Names:

NINTEDANIB DrugBank Drug Name

656247-17-5 CAS Number

Ofev Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories antifibrotic agents

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Alternate Names:

BIBF1120 Development Name

NINTEDANIB Generic Name

VARGATEF Trade Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

CHEMBL502835 ChEMBL Drug ID

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

Alternate Names:

NINTEDANIB Primary Drug Name

VARGATEF Drug Trade Name

BIBF 1120 Drug Synonym

Alternate Names:

D09HNV TTD Drug ID

Alternate Names:

NINTEDANIB GuideToPharmacology Ligand Name